Benjamin Leach, M.D.
"My own approach to patient care is mirrored by the culture at City of Hope - the cornerstone being compassion, innovation and collaboration.
Benjamin Leach, M.D., takes a passionate approach to cancer treatment incorporating leading-edge therapies from precision medicine to immunotherapy, with a relentless commitment to serving his patients and improving their quality of life.
"It's a privilege to be welcomed into patients' lives," he says.
Dr. Leach received his medical degree at Tulane University in New Orleans, completed his internship and residency at Los Angeles County + USC Medical Center and continued his training with a hematology/oncology fellowship at New York-Presbyterian Hospital/Weill Cornell Medical College. At Weill Cornell, he pursued his interest in targeted treatment, studying the WNT signaling pathway implicated in colorectal cancer development, for which he was awarded the Weill Department of Medicine Fellows Award in Research.
Dr. Leach treats patients at City of Hope's Mission Hills, California, facility.
2019, American Board of Internal Medicine, Oncology
2019, American Board of Internal Medicine, Hematology
2014, American Board of Internal Medicine
2011, M.D., Tulane University, New Orleans, Louisiana
2005, B.S., biological sciences, University of Illinois, Chicago, Illinois
2014-2017, Hematology and Oncology, New York-Presbyterian Hospital, Weill Cornell Medical College, New York, New York
2011-2014, Intern and Resident, Department of Medicine, Los Angeles County + USC Medical Center, Los Angeles, California
2017-present, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Mission Hills, CA
2017, Weill Department of Medicine Fellows Award in Research
2020, American Society of Clinical Oncology
- Shen MJ, Gonzalez C, Leach B, Maciejewski PK, Kozlov E, Prigerson HG. An examination of Latino advanced cancer patients' and their informal caregivers' preferences for communication about advance care planning: A qualitative study. Palliat Support Care. 2020 Jun; 18(3): 277-284.
- Rajurkar S, Mambetsariev I, Pharaon R, Leach B, Tan T, Kulkarni P, Salgia R. Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. J Clin Med. 2020 Jun 15; 9(6): 1870.
- Presant CA, Salgia R, Kulkarni P, Tiep BL, Sanani S, Leach B, Ashing K, Sandoval J, Sedrak MS, Landau S, Yeung S, Raz D, Subbiah S. Implementing Lung Cancer Screening and Prevention in Academic Centers, Affiliated Network Offices and Collaborating Care Sites. J Clin Med. 2020 Jun 11; 9(6): 1820.
- Foronda M, Tarumoto Y, Schatoff EM, Leach BI, Diaz BJ, Zimmerman J, Goswami S, Shusterman M, Vakoc CR, Dow LE. Tankyrase inhibition sensitizes cells to CDK4 blockade. PLoS One. 2019 Dec 31; 14(12): e0226645.
- Schatoff, EM, Goswami S, Zafra MP, Foronda M, Shusterman M, Leach BI, Katti A, Diaz BJ, Dow LE. Distinct Colorectal Cancer-Associated APC Mutations Dictate Response to Tankyrase Inhibition. Cancer Discov. 2019 Oct; 9(10): 1358-1371.
- O’Rourke KP, Loizou E, Livshits G, Schato EM, Baslan T, Manchado E, Simon J, Leach BI, Han T, Pauli C, Beltran H, Rubin MA, Dow LE, Lowe SW. Transplantation of engineered organoids enables rapid generation of metastatic mouse models of colorectal cancer. Nature Biotechnology. 2017 Jun; 35(6): 577-582.
- Leach BI, Galletti G, Lam L, Tagawa ST. Mechanisms of resistance to systemic therapy in metastatic castration resistant prostate cancer. Cancer Treat Rev. 2017 Jun; 57: 16-27.
- Schatoff EM, Leach BI, Dow LE. WNT Signaling and Colorectal Cancer. Curr Colorectal Cancer Rep. 2017 Apr; 13(2): 101-110.
- Fedashchin A, Cernota WH, Gonzalez MC, Leach BI, Kwan N, Wesley RK, Weber JM. Random transposon mutagenesis of the Saccharopolyspora erythraea genome reveals additional genes inuencing erythromycin biosynthesis. FEMS Microbiol Lett. 2015 Nov; 362(22)
- Leach BI, Sun B, Petrovic L, Liu SV. Breast metastasis from nasopharyngeal carcinoma: A case report and review of the literature. Oncology Letters. 2013 June; 5 (6): 1859-61.
- Weber JM, Cernota WH, Gonzalez MC, Leach BI, Reeves AR, Wesley RK. An erythromycin process improvement using the diethyl methylmalonate-responsive (Dmr) phenotype of the Saccharopolyspora erythraea mutB strain. Appl Microbiol Biotechnol. 2012 Feb; 93 (4): 1575-83.
- Reeves AR, Brikun IA, Cernota WH, Leach BI, Gonzalez MC, Weber JM. Engineering of the methylmalonyl-CoA metabolite node of Saccharopolyspora erythraea for increased erythromycin production. Metabolic Engineering. 2007 May; 9 (3): 293-303.
- Reeves AR, Brikun IA, Cernota WH, Leach BI, Gonzalez MC, Weber JM. Effects of methylmalonyl-CoA mutase gene knockouts on erythromycin production in carbohydrate-based and oil-based fermentations of Saccharopolyspora erythraea. J Ind Microbiol Biotechnol. 2006 Jul; 33 (7): 600-9.